These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 29068506)

  • 1. Click Chemistry: Novel Applications in Cell Biology and Drug Discovery.
    Gehringer M; Laufer SA
    Angew Chem Int Ed Engl; 2017 Dec; 56(49):15504-15505. PubMed ID: 29068506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromodomains: Structure, function and pharmacology of inhibition.
    Ferri E; Petosa C; McKenna CE
    Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins.
    Fu Y; Zhang Y; Sun H
    Eur J Med Chem; 2021 Dec; 226():113853. PubMed ID: 34547507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
    Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT
    Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Activity Relationship Study of N(6)-Benzoyladenine-Type BRD4 Inhibitors and Their Effects on Cell Differentiation and TNF-α Production.
    Amemiya S; Yamaguchi T; Sakai T; Hashimoto Y; Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(9):1378-83. PubMed ID: 27581642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of BET bromodomains alleviates inflammation in human RPE cells.
    Hytti M; Tokarz P; Määttä E; Piippo N; Korhonen E; Suuronen T; Honkakoski P; Kaarniranta K; Lahtela-Kakkonen M; Kauppinen A
    Biochem Pharmacol; 2016 Jun; 110-111():71-9. PubMed ID: 27106081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling the regulatory interplay of BET bromodomains and Sirtuins in cancer cell lines.
    Järvenpää J; Rahnasto-Rilla M; Lahtela-Kakkonen M; Küblbeck J
    Biomed Pharmacother; 2022 Mar; 147():112652. PubMed ID: 35065514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
    Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological and molecular effects of bromodomain and extra-terminal (BET) inhibitors JQ1, IBET-151, and IBET-762 in OSCC cells.
    Baldan F; Allegri L; Lazarevic M; Catia M; Milosevic M; Damante G; Milasin J
    J Oral Pathol Med; 2019 Mar; 48(3):214-221. PubMed ID: 30618144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reprogramming by De-bookmarking the Somatic Transcriptional Program through Targeting of BET Bromodomains.
    Shao Z; Yao C; Khodadadi-Jamayran A; Xu W; Townes TM; Crowley MR; Hu K
    Cell Rep; 2016 Sep; 16(12):3138-3145. PubMed ID: 27653680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanisms.
    Shi X; Mihaylova VT; Kuruvilla L; Chen F; Viviano S; Baldassarre M; Sperandio D; Martinez R; Yue P; Bates JG; Breckenridge DG; Schlessinger J; Turk BE; Calderwood DA
    Proc Natl Acad Sci U S A; 2016 Aug; 113(31):E4558-66. PubMed ID: 27432991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MCM5 as a target of BET inhibitors in thyroid cancer cells.
    Mio C; Lavarone E; Conzatti K; Baldan F; Toffoletto B; Puppin C; Filetti S; Durante C; Russo D; Orlacchio A; Di Cristofano A; Di Loreto C; Damante G
    Endocr Relat Cancer; 2016 Apr; 23(4):335-47. PubMed ID: 26911376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Click approach to the discovery of 1,2,3-triazolylsalicylamides as potent Aurora kinase inhibitors.
    Song D; Park Y; Yoon J; Aman W; Hah JM; Ryu JS
    Bioorg Med Chem; 2014 Sep; 22(17):4855-66. PubMed ID: 25042560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
    Chen D; Lu T; Yan Z; Lu W; Zhou F; Lyu X; Xu B; Jiang H; Chen K; Luo C; Zhao Y
    Eur J Med Chem; 2019 Nov; 182():111633. PubMed ID: 31461688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bromodomain Drug Discovery - the Past, the Present, and the Future.
    Pervaiz M; Mishra P; Günther S
    Chem Rec; 2018 Dec; 18(12):1808-1817. PubMed ID: 30289209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor.
    Walser A; Flynn T; Mason C; Crowley H; Maresca C; Yaremko B; O'Donnell M
    J Med Chem; 1991 Mar; 34(3):1209-21. PubMed ID: 2002463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Click chemistry enables preclinical evaluation of targeted epigenetic therapies.
    Tyler DS; Vappiani J; Cañeque T; Lam EYN; Ward A; Gilan O; Chan YC; Hienzsch A; Rutkowska A; Werner T; Wagner AJ; Lugo D; Gregory R; Ramirez Molina C; Garton N; Wellaway CR; Jackson S; MacPherson L; Figueiredo M; Stolzenburg S; Bell CC; House C; Dawson SJ; Hawkins ED; Drewes G; Prinjha RK; Rodriguez R; Grandi P; Dawson MA
    Science; 2017 Jun; 356(6345):1397-1401. PubMed ID: 28619718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
    Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
    Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.
    Zhu H; Bengsch F; Svoronos N; Rutkowski MR; Bitler BG; Allegrezza MJ; Yokoyama Y; Kossenkov AV; Bradner JE; Conejo-Garcia JR; Zhang R
    Cell Rep; 2016 Sep; 16(11):2829-2837. PubMed ID: 27626654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.